Latest AMGN news

Amgen price target raised by Jefferies to $410 after positive Sjögren's data

Proactive Investors · Wed, 23 Sep 2026 15:12:55 -0400

Amgen Inc (NASDAQ:AMGN, XETRA:AMG)'s price target was raised to $410 from $367 by Jefferies after dazodalibep delivered positive Phase 3 results in patients with systemic Sjögren's disease. Jefferies said the drug, a CD40L antagonist, achieved a statistically significant and clinically meaningful improvement in the primary endpoint, the change from baseline in ESSDAI at week 48.

Viking's Obesity Edge May Be Staying Power, Not Weight Loss

MarketBeat · Wed, 23 Sep 2026 13:22:25 -0400

Viking Therapeutics NASDAQ: VKTX stock jumped 36% on Sept. 22. The catalyst was new maintenance data for VK2735, its GLP-1/GIP obesity candidate, which showed that patients maintained most of their weight loss after switching from weekly shots to every-other-week or monthly dosing.

AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study

Zacks Investment Research · Wed, 23 Sep 2026 11:40:58 -0400

Amgen's dazodalibep meets its primary goal in a Phase III study, showing sustained improvement in systemic Sjogren's disease activity through week 48.

Amgen Hits Primary Endpoint In Sjögren's Trial, But Approval Filing Awaits Another Trial Data

Benzinga · Tue, 22 Sep 2026 13:56:19 -0400

Amgen Inc. (NASDAQ:AMGN) has reported encouraging topline outcomes from its Phase 3 OASIZ 301 study. The trial assessed the efficacy of dazodalibep in adult patients suffering from Sjögren's disease accompanied by moderate-to-severe systemic disease activity.

Amgen Boasts Success In Sjogren's; Shares Charge Ahead

Investors Business Daily · Tue, 22 Sep 2026 10:07:20 -0400

Amgen stock bounded above its 50-day line Tuesday after publishing promising results for its experimental Sjogren's treatment.

Amgen's autoimmune drug succeeds in late-stage trial

Reuters · Tue, 22 Sep 2026 09:01:49 -0400

Amgen said on Tuesday its experimental drug to treat an autoimmune disease that attacks the body's moisture-producing ‌glands met the main goal of reducing disease activity in a late-stage trial.

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE

PRNewsWire · Tue, 22 Sep 2026 09:00:00 -0400

Dazodalibep Demonstrated Statistically Significant and Clinically Meaningful Improvement in Systemic Disease Activity Results Support the Potential for a New, Highly Differentiated Treatment Option for People Living With a Debilitating Autoimmune Disease THOUSAND OAKS, Calif., Sept. 22, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive topline results from the Phase 3 OASIZ 301 study evaluating dazodalibep in adults with Sjögren's disease and moderate-to-severe systemic disease activity.

Market information is provided for research and visualization and is not investment advice.